U.S. prevalence of endocrine therapy-naïve locally advanced or metastatic breast cancer.
Breast cancer, advanced
breast cancer, metastatic
electronic health records
endocrine therapy
hormone receptor–positive disease
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
entrez:
3
5
2019
pubmed:
3
5
2019
medline:
1
4
2020
Statut:
ppublish
Résumé
Variations in treatment choice, or late stage at first diagnosis, mean that, despite guideline recommendations, not all patients with hormone receptor (hr)-positive locally advanced or metastatic breast cancer (la/mbca) will have received endocrine therapy before disease progression. In the present study, we aimed to estimate the proportion of women with postmenopausal hr-positive la/mbca in the United States who are endocrine therapy-naïve. Women in the Optum Electronic Health Record (ehr) database with a breast cancer (bca) diagnosis (January 2008-March 2015) were included. Patient and malignancy characteristics were identified using structured data fields and natural-language processing of free-text clinical notes. The proportion of women with postmenopausal hr-positive, human epidermal growth factor 2 (her2)-negative (or unknown) la/mbca who had not received prior endocrine therapy was determined. Results were extrapolated to the entire U.S. population using the U.S. National Cancer Institute's Surveillance, Epidemiology, and End Results database. Results are presented descriptively. In the ehr database, 11,831 women with bca had discernible information on postmenopausal status, hr status, and disease stage. Of those women, 1923 (16.3%) had postmenopausal hr-positive, her2-negative (or unknown) la/mbca, and 70.7% of those 1923 patients ( A substantial proportion of women with postmenopausal hr-positive la/mbca in the United States could be endocrine therapy-naïve.
Sections du résumé
Background
Variations in treatment choice, or late stage at first diagnosis, mean that, despite guideline recommendations, not all patients with hormone receptor (hr)-positive locally advanced or metastatic breast cancer (la/mbca) will have received endocrine therapy before disease progression. In the present study, we aimed to estimate the proportion of women with postmenopausal hr-positive la/mbca in the United States who are endocrine therapy-naïve.
Methods
Women in the Optum Electronic Health Record (ehr) database with a breast cancer (bca) diagnosis (January 2008-March 2015) were included. Patient and malignancy characteristics were identified using structured data fields and natural-language processing of free-text clinical notes. The proportion of women with postmenopausal hr-positive, human epidermal growth factor 2 (her2)-negative (or unknown) la/mbca who had not received prior endocrine therapy was determined. Results were extrapolated to the entire U.S. population using the U.S. National Cancer Institute's Surveillance, Epidemiology, and End Results database. Results are presented descriptively.
Results
In the ehr database, 11,831 women with bca had discernible information on postmenopausal status, hr status, and disease stage. Of those women, 1923 (16.3%) had postmenopausal hr-positive, her2-negative (or unknown) la/mbca, and 70.7% of those 1923 patients (
Conclusions
A substantial proportion of women with postmenopausal hr-positive la/mbca in the United States could be endocrine therapy-naïve.
Identifiants
pubmed: 31043825
doi: 10.3747/co.26.4163
pii: conc-26-e180
pmc: PMC6476436
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Receptors, Estrogen
0
Receptors, Progesterone
0
Receptors, Steroid
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e180-e187Déclaration de conflit d'intérêts
CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare the following interests: TD, JL, and NJ are employees of, and receive a salary from, AstraZeneca; APN, CL, EG, MD, and JDS are employees of Optum Epidemiology, which conducted this research under a contract with AstraZeneca; APN and JDS also own stock in United Health Group; TD owns stock in Achillion Pharmaceuticals, AstraZeneca, Bristol–Myers Squibb, Gilead, Inovio Pharmaceuticals, and Roche. WJG has no conflicts to disclose.
Références
Ann Oncol. 2017 Jan 1;28(1):16-33
pubmed: 28177437
Ann Oncol. 2010 Nov;21(11):2169-74
pubmed: 20427349
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
J Clin Oncol. 2010 Aug 10;28(23):3784-96
pubmed: 20625130
J Comp Eff Res. 2015 Aug;4(4):303-14
pubmed: 26274792
Diabetes Res Clin Pract. 2016 Nov;121:192-203
pubmed: 27744128
World J Clin Oncol. 2014 Aug 10;5(3):465-77
pubmed: 25114860
Ann Oncol. 2014 Oct;25(10):1871-88
pubmed: 25234545
J Clin Oncol. 2014 Jul 20;32(21):2255-69
pubmed: 24868023
Lancet. 2017 Dec 17;388(10063):2997-3005
pubmed: 27908454
Breast. 2014 Oct;23(5):489-502
pubmed: 25244983
J Natl Cancer Inst. 2000 Apr 5;92(7):550-6
pubmed: 10749910
Ann Oncol. 2012 Aug;23 Suppl 6:vi52-5
pubmed: 23012304
Breast. 2017 Feb;31:114-120
pubmed: 27837704
J Nippon Med Sch. 2014;81(3):139-47
pubmed: 24998960
Breast. 2017 Feb;31:244-259
pubmed: 27927580
Cancer. 2014 Dec 1;120 Suppl 23:3771-80
pubmed: 25412389
Br J Cancer. 2015 Apr 28;112(9):1445-51
pubmed: 25880008
J Natl Cancer Inst. 2014 Apr 28;106(5):
pubmed: 24777111
Clin Transl Oncol. 2015 Nov;17(11):895-902
pubmed: 26081286